Ultragenyx Pharmaceutical Inc. (RARE) Balance Sheet

The deterioration reflects accumulated losses, with retained earnings sliding from -$3.7B to -$4.9B, which mirrors the sustained operating burn seen in the income and cash flow data. The 2025Q4 cash spike to $434.0M appears to be a timing or financing event rather than a durable reversal, since cash resumed its decline in subsequent quarters. Investors should monitor whether the negative equity position constrains future financing flexibility.

The jump in debt during 2025Q3, with a debt-to-equity ratio spiking to 54.76 as equity briefly approached zero, suggests a shift from minimal borrowing toward a more leveraged capital structure. Because liabilities now exceed assets, the company depends on continued access to capital markets to service obligations. Refinancing terms and maturity profile are not detailed in the supplied data, so their risk cannot be fully assessed here.

A current ratio near 1.4 to 2.5 suggests short-term obligations are covered, but the cash balance alone is modest relative to the scale of quarterly operating burn. The temporary cash build to $434.0M in 2025Q4 appears to have been consumed within three quarters, indicating limited runway without new financing. Investors should treat the current liquidity position as adequate in the near term but vulnerable to any delay in pipeline or partnership milestones.

The asset mix is consistent with a commercial-stage biotech that outsources much of its manufacturing rather than owning a large fixed-asset footprint, though PP&E has drifted down about 17% over the period. Goodwill is small relative to total assets, so impairment risk appears limited on the balance sheet. The primary value of the company likely resides in intangibles and pipeline assets that are not fully captured in these reported figures.